Panacea Biotech Secures $8.9M More Vaccine Orders from UNICEF

• Panacea Biotech received an $8.9 million update to its UNICEF contract for pentavalent vaccine Easyfive-TT (DTwP-HepB-Hib) for 2023-2027.
• The contract value for 2026 increased by $2.55 million to $16.8 million, and for 2027 by $2.70 million to $15.18 million.
• A new award for 2027 worth $3.68 million was also secured.
• UNICEF previously placed a significant order for polio vaccines (bOPV) from Panacea Biotech for 2026-2030.
• Panacea Biotech shares rose 0.93% to ₹359.50 on NSE on December 24 following the news.

Why It Matters: Panacea Biotech strengthens its partnership with UNICEF, securing substantial new vaccine orders.